Publications by authors named "M J Smalley"

Neurological and cardiac injuries are significant contributors to morbidity and mortality following pediatric in-hospital cardiac arrest (IHCA). Preservation of mitochondrial function may be critical for reducing these injuries. Dimethyl fumarate (DMF) has shown potential to enhance mitochondrial content and reduce oxidative damage.

View Article and Find Full Text PDF

Background: Bacterial cancer therapy was first trialled in patients at the end of the nineteenth century. More recently, tumour-targeting bacteria have been harnessed to deliver plasmid-expressed therapeutic interfering RNA to a range of solid tumours. A major limitation to clinical translation of this is the short-term nature of RNA interference in vivo due to plasmid instability.

View Article and Find Full Text PDF

LYN kinase is expressed in BRCA1 loss-of-function-dependent mouse mammary tumours, in the cells of origin of such tumours, and in human breast cancer. Suppressing LYN kinase activity in BRCA1-defective cell lines as well as in in vitro cultures of Brca1-null mouse mammary tumours is deleterious to their growth. Here, we examined the interaction between LYN kinase and BRCA1 loss-of-function in an in vivo mouse mammary tumour model, using conditional knockout Brca1 and Lyn alleles.

View Article and Find Full Text PDF

A better understanding of the mechanisms generating tumour heterogeneity will allow better targeting of current therapies, identify potential resistance mechanisms and highlight new approaches for therapy. We have previously shown that in genetically modified mouse models carrying conditional oncogenic alleles, mammary tumour histotype varies depending on the combination of alleles, the cell type to which they are targeted and, in some cases, reproductive history. This suggests that tumour heterogeneity is not a purely stochastic process; rather, differential activation of signalling pathways leads to reproducible differences in tumour histotype.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluates the safety and effectiveness of a T cell receptor fusion construct, gavo-cel, in patients with mesothelin-expressing solid tumors who did not respond to previous treatments, participating in a phase 1/2 trial.
  • - The recommended phase 2 dose (RP2D) was set at 1 × 10^6 cells per m² after lymphodepletion, with some serious toxicities observed, including pneumonitis and bronchioalveolar hemorrhage.
  • - Initial results show a 20% overall response rate and a 70% 6-month overall survival rate, suggesting gavo-cel's potential effectiveness but also highlighting concerns about its safety and the need for
View Article and Find Full Text PDF